© 2021 MJH Life Sciences and Cure Today. All rights reserved.
© 2021 MJH Life Sciences™ and Cure Today. All rights reserved.
April 23, 2020
Looking at new data from the phase 3 PEARL trial, Dr. Melissa K. Accordino discusses how the use of CDK4/6 inhibitors could help patients with HR-positive/HER2-negative metastatic breast cancer move away from chemotherapy.
Unconventional Candidate For a Lung Cancer Hero
Perhaps a Pearl: An Experience That Led to Meeting Another Breast Cancer Survivor
An Oncology Nurse Wears Many Hats
Inaccurate Information on Cancer Diagnosis and Treatment Common on Social Media Sites